CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board

CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020.

CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's EpiSmart approach is a cross-linking system designed to treat keratoconus without disrupting the epithelium, allowing for a rapid return to normal activities.

Dr. Talamo, an ophthalmic surgeon with over 25 years in clinical practice, is a leader in corneal disease, cataract, and refractive surgery. After 25 years in the clinic, he pivoted to executive roles in biomedicine and healthcare. He served as Chief Medical Officer of Ocular Therapeutix and Chief Medical Officer and Worldwide Vice President of Clinical and Medical Affairs at Johnson & Johnson Vision.

“I am thrilled to work more closely with the CXLO Board as we develop the minimally-invasive EpiSmart cross-linking system to improve patient comfort and preserve vision,” Dr. Talamo said in a company news release. “I look forward to collaborating with the CXLO team to improve safety and clinical outcomes for patients with keratoconus.”